These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 3360152)
1. Amplification and over-expression of the neu oncogene in human breast carcinomas. van de Vijver MJ; Mooi WJ; Peterse JL; Nusse R Eur J Surg Oncol; 1988 Apr; 14(2):111-4. PubMed ID: 3360152 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. van de Vijver MJ; Mooi WJ; Wisman P; Peterse JL; Nusse R Oncogene; 1988 Feb; 2(2):175-8. PubMed ID: 3285295 [TBL] [Abstract][Full Text] [Related]
3. Amplification of HER-2(erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Imyanitov EN; Chernitsa OI; Serova OM; Nikoforova IF; Pluzhnikova GF; Knyazev PG Neoplasma; 1993; 40(1):35-9. PubMed ID: 7688867 [TBL] [Abstract][Full Text] [Related]
4. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689 [TBL] [Abstract][Full Text] [Related]
5. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
6. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Persons DL; Borelli KA; Hsu PH Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184 [TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of HER-2/neu gene amplification in paraffin embedded tumour tissue in women with breast cancer. Zadrozny M; Smolarz B; Romanowicz-Makowska H; Kozłowska E; Kulig A Pol J Pathol; 2002; 53(4):189-93. PubMed ID: 12597335 [TBL] [Abstract][Full Text] [Related]
8. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Singleton TP; Strickler JG Pathol Annu; 1992; 27 Pt 1():165-90. PubMed ID: 1346551 [TBL] [Abstract][Full Text] [Related]
9. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease. Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression. Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167 [TBL] [Abstract][Full Text] [Related]
11. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
12. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Varley JM; Swallow JE; Brammar WJ; Whittaker JL; Walker RA Oncogene; 1987; 1(4):423-30. PubMed ID: 3330785 [TBL] [Abstract][Full Text] [Related]
13. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540 [TBL] [Abstract][Full Text] [Related]
14. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Press MF; Hung G; Godolphin W; Slamon DJ Cancer Res; 1994 May; 54(10):2771-7. PubMed ID: 7909495 [TBL] [Abstract][Full Text] [Related]
15. Assessing sequential oncogene amplification in human breast cancer. Janocko LE; Lucke JF; Groft DW; Brown KA; Smith CA; Pollice AA; Singh SG; Yakulis R; Hartsock RJ; Shackney SE Cytometry; 1995 Sep; 21(1):18-22. PubMed ID: 8529465 [TBL] [Abstract][Full Text] [Related]
16. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Kerns BJ; Jordan PA; Huper G; Marks JR; Iglehart JD; Layfied LJ Mod Pathol; 1993 Nov; 6(6):673-8. PubMed ID: 7905629 [TBL] [Abstract][Full Text] [Related]
17. [Amplification of protooncogenes and expression of the HER2/neu oncogene in invasive breast cancer]. Ben-Aharon U; Gutman M; Shani E; Chatsubi I; Pfefferman R; Shiloh Y; Tal M Harefuah; 1996 Jan; 130(1):4-8, 72. PubMed ID: 8682380 [TBL] [Abstract][Full Text] [Related]
18. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Shin SJ; Hyjek E; Early E; Knowles DM Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. Homaei-Shandiz F; Ghavam-Nassiri MR; Sharifi N; Homaei-Shandiz AH; Taghizadeh-Kermani A; Torshizi SA; Ghafarzadegan K Saudi Med J; 2006 Dec; 27(12):1810-4. PubMed ID: 17143354 [TBL] [Abstract][Full Text] [Related]
20. The role of the HER-2/neu oncogene in gynecologic cancers. Cirisano FD; Karlan BY J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]